Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY
Holding HKMPY?
Track your performance easily
HKMPY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.84 - $53.68
Previous Close$49.84
Volume686.00
Average Volume (3M)135.00
Market Cap
$5.47B
Enterprise Value$6.54B
Total Cash (Recent Filing)$205.00M
Total Debt (Recent Filing)$1.19B
Price to Earnings (P/E)19.4
Beta0.41
Next Earnings
Feb 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 19, 2024Dividend Yield3.07%
Share Statistics
EPS (TTM)2.57
Shares Outstanding110,943,227
10 Day Avg. Volume1,908
30 Day Avg. Volume135
Standard Deviation0.09
R-Squared0.04
Alpha0.00136
Financial Highlights & Ratios
Price to Book (P/B)4.90
Price to Sales (P/S)1.93
Price to Cash Flow (P/CF)14.70
P/FCF Ratio20.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.71
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HKMPY FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest stock price was $43.84 and its highest was $53.68 in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Currently, no data Available
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Feb 20, 2025 which is in 70 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Aug 08, 2024. The company reported $2.038 earnings per share for the quarter, beating the consensus estimate of N/A by $2.038.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Overvalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC pays a Semiannually dividend of $0.62 which represents an annual dividend yield of 3.07%. See more information on Hikma Pharmaceuticals PLC dividends here
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 110,943,230 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of $2.038 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.213%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in HKMPY
---
Hikma Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.92%
12-Months-Change
Fundamentals
Return on Equity
12.72%
Trailing 12-Months
Asset Growth
4.94%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and are sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
---
Technical Analysis
Jazz Pharmaceuticals
―
Bausch Health Companies
―
Perrigo Company
―
ACADIA Pharmaceuticals
―
---